GELTEQ LIMITED ORDINARY SHARES
NASDAQ: GELS (Gelteq Limited)
Kemas kini terakhir: 16 jam lalu1.09
-0.01 (-0.91%)
| Penutupan Terdahulu | 1.10 |
| Buka | 1.05 |
| Jumlah Dagangan | 312,360 |
| Purata Dagangan (3B) | 1,090,109 |
| Modal Pasaran | 11,675,056 |
| Harga / Jualan (P/S) | 91.97 |
| Harga / Buku (P/B) | 1.11 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,518.17% |
| EPS Cair (TTM) | -0.350 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 56.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 25.43% |
| Nisbah Semasa (MRQ) | 0.080 |
| Aliran Tunai Operasi (OCF TTM) | -1.07 M |
| Pulangan Atas Aset (ROA TTM) | -8.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Gelteq Limited | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.13 |
|
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| % Dimiliki oleh Orang Dalam | 60.36% |
| % Dimiliki oleh Institusi | 1.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wedbush Securities Inc | 30 Sep 2025 | 20,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Dec 2025 | Pengumuman | Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform |
| 02 Dec 2025 | Pengumuman | Gelteq to Present at Investor Summit Virtual on December 9, 2025 |
| 24 Nov 2025 | Pengumuman | Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform |
| 23 Oct 2025 | Pengumuman | Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform |
| 09 Oct 2025 | Pengumuman | Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound |
| 12 Sep 2025 | Pengumuman | Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |